Item 8

  

Other Contingencies

We also are subject to a variety of other claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes that resolving claims against us, individually or in aggregate, will not have a material adverse impact in our consolidated financial statements, these matters are subject to inherent uncertainties and management’s view of these matters may change in the future.

As of June 30, 2025, we accrued aggregate legal liabilities of $ 541  million. While we intend to defend these matters vigorously, adverse outcomes that we estimate could reach approximately $ 600  million in aggregate beyond recorded amounts are reasonably possible. Were unfavorable final outcomes to occur, there exists the possibility of a material adverse impact in our consolidated financial statements for the period in which the effects become reasonably estimable.

  

NOTE 15 — STOCKHOLDERS’ EQUITY

Shares Outstanding

  

Shares of common stock outstanding were as follows:

> **(In millions)**
>
> Year Ended June 30, ..................... 2025 / 2025 / 2024 / 2024 / 2023 / 2023
> Balance, beginning of year .............. 7,434 / 7,432 / 7,464
> Issued .................................. 31 / 34 / 37
> Repurchased ............................. ( 31 / ) / ( 32 / ) / ( 69 / )
> Balance, end of year .................... 7,434 / 7,434 / 7,432

Share Repurchases

On September 14, 2021, our Board of Directors approved a share repurchase program authorizing up to $ 60.0  billion in share repurchases. This share repurchase program commenced in November 2021 and was completed in April 2025.

On September 16, 2024, our Board of Directors approved a share repurchase program authorizing up to $ 60.0  billion in share repurchases. This share repurchase program commenced in April 2025, following completion of the program approved on September 14, 2021, has no expiration date, and may be terminated at any time. As of June 30, 2025, $ 57.3  billion remained of this $ 60.0  billion share repurchase program.

  

We repurchased the following shares of common stock under the share repurchase programs:

> **(In millions)**
>
> Shares / Shares / Amount / Amount / Shares / Shares / Amount / Amount / Shares / Shares / Amount / Amount
>
> Year Ended June 30, ..................... 2025 / 2025 / 2025 / 2025 / 2025 / 2025 / 2024 / 2024 / 2024 / 2024 / 2024 / 2024 / 2023 / 2023 / 2023 / 2023 / 2023 / 2023
> First Quarter ........................... 7 / $ / 2,800 / 11 / $ / 3,560 / 17 / $ / 4,600
> Second Quarter .......................... 8 / 3,500 / 7 / 2,800 / 20 / 4,600
> Third Quarter ........................... 8 / 3,500 / 7 / 2,800 / 18 / 4,600
> Fourth Quarter .......................... 8 / 3,200 / 7 / 2,800 / 14 / 4,600
> Total ................................... 31 / $ / 13,000 / 32 / $ / 11,960 / 69 / $ / 18,400

All repurchases were made using cash resources. Shares repurchased during the fourth quarter of fiscal year 2025 were under the share repurchase programs approved on September 14, 2021 and September 16, 2024. All other shares repurchased were under the share repurchase program approved on September 14, 2021. The above table excludes shares repurchased to settle employee tax withholding related to the vesting of stock awards of $ 5.4  billion, $ 5.3  billion, and $ 3.8  billion for fiscal years 2025, 2024, and 2023, respectively.

  

79

---

  

PART II